Alcon To Try Glaxo’s Ariflo For Dry Eye
This article was originally published in The Pink Sheet Daily
Executive Summary
Swiss firm builds pipeline with help from GSK and Origenis in latest eye care in-licensing deals.
You may also be interested in...
Forest Acquires U.S. Rights To Nycomed's Oral COPD Drug Daxas
After long development haul, PDE-4 inhibitor finally gets adopted by a commercial parent, ahead of approval.
Forest Acquires U.S. Rights To Nycomed's Oral COPD Drug Daxas
After long development haul, PDE-4 inhibitor finally gets adopted by a commercial parent, ahead of approval.
Nycomed Says Phase III Daxas COPD Data Show Drug Is Ready For A Second Shot
The privately held European pharma is looking for a U.S. partner to commercialize the potentially first-in-class PDE4 inhibitor.